John Powderly
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Immunology top 0.1%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 53
- Cancer Immunotherapy and Biomarkers 39
- CAR-T cell therapy research 10
- Peptidase Inhibition and Analysis 6
- HER2/EGFR in Cancer Research 5
- Immunology 15
- Immunotherapy and Immune Responses 10
- Co-authors
- Julie Renee Brahmer (5 shared papers)Suzanne Louise Topalian (5 shared papers)Charles G. Drake (3 shared papers)IRA S. WOLLNER (2 shared papers)Theresa M. Salay (2 shared papers)Elizabeth Stankevich (2 shared papers)Changyu Wang (2 shared papers)Marta M. Gilson (2 shared papers)
- Journals
- Annals of Oncology (25 papers)Journal of Clinical Oncology (10 papers)Clinical Cancer Research (8 papers)Journal for ImmunoTherapy of Cancer (5 papers)European Journal of Cancer (4 papers)
- Partner nations
- United StatesFranceSpain
In The Last Decade
John Powderly
80 papers receiving 25.4k citations
John Powderly's Hit Papers
Peers
Comparison fields: 5 of 136
- Oncology 18.4k
- Immunology 10.0k
- Pulmonary and Respiratory Medicine 4.9k
- Cancer Research 1.8k
- Genetics 672
Countries citing papers authored by John Powderly
This map shows the geographic impact of John Powderly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Powderly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Powderly more than expected).
Fields of papers citing papers by John Powderly
This network shows the impact of papers produced by John Powderly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Powderly. The network helps show where John Powderly may publish in the future.
Co-authors
The 25 scholars most cited alongside John Powderly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 81 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Hit paper breakdown → | 2012 | 10591 |
| 2 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Hit paper breakdown → | 2014 | 4417 |
| 3 | Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates Hit paper breakdown → | 2010 | 2584 |
| 4 | Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab Hit paper breakdown → | 2014 | 1961 |
| 5 | Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 1010 |
| 6 | Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study Hit paper breakdown → | 2018 | 610 |
| 7 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 496 |
| 8 | Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab Hit paper breakdown → | 2019 | 484 |
| 9 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study Hit paper breakdown → | 2016 | 467 |
| 10 | 2008 | 400 | |
| 11 | Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab Hit paper breakdown → | 2015 | 382 |
| 12 | 2014 | 325 | |
| 13 | 2019 | 278 | |
| 14 | 2010 | 259 | |
| 15 | 2018 | 246 | |
| 16 | 2019 | 128 | |
| 17 | 2011 | 122 | |
| 18 | 2018 | 118 | |
| 19 | 2012 | 89 | |
| 20 | 2020 | 73 |
About John Powderly
John Powderly is a scholar working on Oncology, Immunology, Physiology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 81 papers that have together received 26.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (10 papers), Immunotherapy and Immune Responses (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Adenosine and Purinergic Signaling (7 papers), Peptidase Inhibition and Analysis (6 papers), Lung Cancer Treatments and Mutations (6 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Oncology (18.4k citations), Immunology (10.0k citations), Pulmonary and Respiratory Medicine (4.9k citations), Cancer Research (1.8k citations) and Genetics (672 citations). John Powderly has collaborated with scholars based in United States, France and Spain. Frequent co-authors include Julie Renee Brahmer, Suzanne Louise Topalian, Charles G. Drake, IRA S. WOLLNER, Theresa M. Salay, Elizabeth Stankevich, Changyu Wang, Marta M. Gilson, Drew Pardoll and Janis Marie Taube. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.